The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Validity of Computed Tomography Versus Magnetic Resonance Imaging in Predicting Muscular Invasion of Bladder Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06046469
Recruitment Status : Recruiting
First Posted : September 21, 2023
Last Update Posted : September 21, 2023
Sponsor:
Information provided by (Responsible Party):
Abdulrhman Ismail Abdulrhman Elkhouly, Menoufia University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of this work is to compare validity between CT and MRI in detecting muscular invasion in Patients with bladder cancer.

Condition or disease Intervention/treatment Phase
Bladder Cancer Diagnostic Test: CT with contrast Diagnostic Test: MRI pelvis Procedure: TURBT Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 55 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Validity of Computed Tomography Versus Magnetic Resonance Imaging in Predicting Muscular Invasion of Bladder Cancer
Actual Study Start Date : September 1, 2022
Estimated Primary Completion Date : December 1, 2023
Estimated Study Completion Date : March 1, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: CT group
this group of patient is doing CT abdomen and plevis with IV contrast then they undergo TURBT and compare the radiological staging to histopathological staging.
 Diagnostic Test: CT with contrast
CT abdomen and pelvis with IV contrast

Procedure: TURBT
transurethral resection of bladder tumor
Active Comparator: MRI group
this group of patient is doing MRI pelvis with contrast then they undergo TURBT and compare the radiological staging to histopathological staging.
 Diagnostic Test: MRI pelvis
MRI pelvis with contrast

Procedure: TURBT
transurethral resection of bladder tumor


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. which is better to detect muscular invasion in bladder cancer CT vs MRI [ Time Frame: 1 month ]
    the radiological staging of CT and MRI compared to histopathological staging


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with urinary bladder mass

Exclusion Criteria:

  • bleeding tendency ,patients had chemo , radiotherapy
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06046469


Contacts
Layout table for location contacts
Contact: ABDULRHMAN IS ELKHOULY, bachelor 01010054452 ext 02 abdo.elkholy20@yahoo.com

Locations
Layout table for location information
Egypt
Faculty of Medicine Menofia University Recruiting
Shibīn Al Kawm, Menofia, Egypt, 32511
Contact: AHMED F AHMED, professor    2224886 ext 2048    ahmed.elkased@med.menofia.edu.eg   
Sponsors and Collaborators
Menoufia University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Abdulrhman Ismail Abdulrhman Elkhouly, Abdulrahman Ismail Elkhouly, Menoufia University
ClinicalTrials.gov Identifier: NCT06046469    
Other Study ID Numbers: CT vs MRI in bladder cancer
First Posted: September 21, 2023    Key Record Dates
Last Update Posted: September 21, 2023
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Female Urogenital Diseases
 Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Urinary Bladder Diseases
Urologic Diseases
Male Urogenital Diseases